Conversely, in pancreatic cancer p57 is targeted by miR92-a, and miR92-a is downregulated in chemoresistant cancer stem cells, leading to p57 upregulation, which promotes cancer stem cell quiescence and treatment resistance (Cioffi et al., 2015). Here, CDKN1C is linked to pancreatic neoplasm.